VIRMA (Vir Like M6A Methyltransferase Associated)

Mechanistically, KIAA1429 directly binds to the 3' untranslated region (3' UTR) of MYC mRNA and catalyzes site-specific m6A methylation, thereby enhancing transcript stability and augmenting MYC protein expression. Collectively, these findings identify KIAA1429 as a critical m6A-dependent post-transcriptional regulator of MYC and nominate the KIAA1429-MYC regulatory axis as a promising therapeutic target in ccRCC.

A functional role of VIRMA is confirmed in knockdown experiments that reveal reduced 3'-UTR methylation and oncogenic phenotypes of bladder cancer cells. Our study is the first to describe the m6A epitranscriptomic landscape of cancer at single-base resolution and provides first insights into the processes that generate its characteristic signatures.

PCR and WB analysis showed that m6A regulators could act on immune-related sites, interact with immune tolerance, and inhibit it. This study indicates that KIAA1429, METTL3, PRRC2A, RBMX, and ZC3H3 may be potential immunotherapeutic targets and biomarkers in HCC.

Our systematic machine learning analysis demonstrates that m6A regulators can effectively predict CRC prognosis and immunotherapy response. The eight-gene signature provides a practical tool for clinical risk assessment and treatment decision-making.

Importantly, two clinical drugs, the RhoA inhibitor simvastatin and the YAP1/TEAD inhibitor verteporfin were determined to be the disruptors of this feed-forward signaling axis, inhibiting ICC tumor growth. These findings reveal the vital function of ANLN in ICC growth and provide promising treatment strategies for ICC.

The translational potential of targeting KIAA1429 is further questioned by the lack of assessment regarding on-target toxicities in normal cells, such as osteoblasts and mesenchymal stem cells, and the foreseeable resistance mechanisms via functional redundancy within the m6A machinery. This commentary urges a more nuanced interpretation of the data and highlights the formidable pharmacological challenges that must be overcome before KIAA1429 can be considered a viable therapeutic target.

Our study constructed a novel signature associated with m6A modifications, which can serve as a promising prognostic indicator for LUAD. These findings may provide valuable insights into diagnosis and therapeutic strategies for patients with LUAD.

In summary, m6A methyltransferase KIAA1429 suppressed CRC tumor immunity by upregulating PD-L1 expression and reducing CD8+T cells infiltration. Targeting KIAA1429 might improve CRC anti-tumor immunity and enhance the efficacy of CRC immunotherapy.

The outcomes of qRT-PCR, immunoblotting and MeRIP assay confirmed a positive association between KIAA1429 and FAM84B. Furthermore, KIAA1429 silencing partially decreased β-catenin levels and reversed the malignant effects of FAM84B overexpression on CRC cells, both in vitro and in vivo. The results illustrate that KIAA1429 promotes CRC tumorigenesis by stabilizing FAM84B mRNA and activating the Wnt/β-catenin pathway, highlighting its capability as a prognostic biomarker and therapeutic target for CRC.

Phosphorylated LDHA (Y10) promotes EV-circSEPT9 secretion, elevating intracellular circSEPT9 levels in recipient TNBC cells. By functioning as a competing endogenous RNA (ceRNA) that sponges miR-515-5p, circSEPT9 upregulates KIAA1429, augments m6A methylation, and drives the development of chemoresistance.

However, challenges remain regarding the resolution of m6A profiling, therapeutic selectivity to avoid unwanted toxicity and biomarker validation for clinical use. This review summarizes the discovery and features of CSCs, highlights the functional role of m6A in GCSCs, and explores diagnostic and therapeutic opportunities while outlining key difficulties for clinical translation.

This review comprehensively examines the dysregulated expression patterns and functions of KIAA1429 in NSCLC, elucidating its m6A-dependent modulation of key downstream effectors (Such as the HOXA1, DAPK3, and BTG2) that orchestrate malignant transformation. We highlight the emerging potential of KIAA1429 as a novel molecular target for precision therapy in NSCLC.